
Trump Plans His Tariff ‘Liberation Day’ With More Targeted Push
Bloomberg Businessweek
Navigating the Weight Loss Drug Landscape
This chapter explores the evolving market for weight loss medications, focusing on key players like Novo Nordisk and Eli Lilly. It discusses the implications of GLP-1 drugs for obesity and diabetes management, the importance of a holistic approach to treatment, and the risks associated with unsupervised medication use. Additionally, it examines the multifaceted nature of obesity, emphasizing that effective management requires more than just dietary changes.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.